<SEC-DOCUMENT>0001764013-22-000083.txt : 20220805
<SEC-HEADER>0001764013-22-000083.hdr.sgml : 20220805
<ACCEPTANCE-DATETIME>20220805070736
ACCESSION NUMBER:		0001764013-22-000083
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20220805
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220805
DATE AS OF CHANGE:		20220805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immunovant, Inc.
		CENTRAL INDEX KEY:			0001764013
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				832771572
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38906
		FILM NUMBER:		221138578

	BUSINESS ADDRESS:	
		STREET 1:		320 WEST 37TH STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10018
		BUSINESS PHONE:		917-580-3099

	MAIL ADDRESS:	
		STREET 1:		320 WEST 37TH STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10018

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Health Sciences Acquisitions Corp
		DATE OF NAME CHANGE:	20190108
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>imvt-20220805.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:0bd1ddaa-ab60-4adc-889e-0e588e84478b,g:a9c6a1e5-c9ea-4488-82d8-47e44a56cdfe,d:2730ca93fc8e4cb0bb934ec18c372901--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>imvt-20220805</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV80L2ZyYWc6YTQwNWU5ZmRiNTIzNDBmNGIzMjI5YWQ3MzA4YzMzYTEvdGFibGU6OGJjMTgwNDlmYmM0NDVlY2I2NWI1MTNiNGM1YmY4NzgvdGFibGVyYW5nZTo4YmMxODA0OWZiYzQ0NWVjYjY1YjUxM2I0YzViZjg3OF8xLTEtMS0xLTQyMDk4_a23eab3a-0061-445a-a8d1-d6edf0a36211">0001764013</ix:nonNumeric><ix:nonNumeric contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV80L2ZyYWc6YTQwNWU5ZmRiNTIzNDBmNGIzMjI5YWQ3MzA4YzMzYTEvdGFibGU6OGJjMTgwNDlmYmM0NDVlY2I2NWI1MTNiNGM1YmY4NzgvdGFibGVyYW5nZTo4YmMxODA0OWZiYzQ0NWVjYjY1YjUxM2I0YzViZjg3OF8yLTEtMS0xLTQyMDk4_1bf6c508-4dbe-4cca-a8b0-beda1a317a97">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="imvt-20220805.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764013</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-05</xbrli:startDate><xbrli:endDate>2022-08-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2730ca93fc8e4cb0bb934ec18c372901_1"></div><div style="min-height:18.39pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;padding-right:-0.07pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="padding-right:-0.07pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:12pt;padding-right:-0.07pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.911%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGV4dHJlZ2lvbjoxZDc2MWY2ZGY0MTA0ZGRlOTcyMWRlMWQ2YzNjZTczZF8xNTMw_0d2ef706-9bfc-49cf-bc24-00b3f4b1dfd0">8-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.911%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt;padding-left:0.4pt;padding-right:0.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="padding-right:-0.07pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="padding-right:-0.07pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGV4dHJlZ2lvbjoxZDc2MWY2ZGY0MTA0ZGRlOTcyMWRlMWQ2YzNjZTczZF8yMjg_ca15383d-f1f3-48b4-b794-3f519fab669b">August 5, 2022</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.911%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:21pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGV4dHJlZ2lvbjoxZDc2MWY2ZGY0MTA0ZGRlOTcyMWRlMWQ2YzNjZTczZF8xNTI0_49c1d528-fb70-4410-83ec-f84d041ee312">IMMUNOVANT, INC.</ix:nonNumeric></span></div><div style="margin-bottom:12pt;padding-right:-0.07pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its Charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.911%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="padding-right:-0.07pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.190%"><tr><td style="width:1.0%"></td><td style="width:19.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.294%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGFibGU6YjJhNGM2OTM3MjJjNGY5YjhlNTZjNDMxMDk1NDAzMjcvdGFibGVyYW5nZTpiMmE0YzY5MzcyMmM0ZjliOGU1NmM0MzEwOTU0MDMyN18wLTAtMS0xLTQyMDk4_97d7c6a7-36c4-46e0-ba08-782d3a387cb8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGFibGU6YjJhNGM2OTM3MjJjNGY5YjhlNTZjNDMxMDk1NDAzMjcvdGFibGVyYW5nZTpiMmE0YzY5MzcyMmM0ZjliOGU1NmM0MzEwOTU0MDMyN18wLTItMS0xLTQyMDk4_9ad0599e-4cf0-4005-8db4-f3b97b0933e5">001-38906</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGFibGU6YjJhNGM2OTM3MjJjNGY5YjhlNTZjNDMxMDk1NDAzMjcvdGFibGVyYW5nZTpiMmE0YzY5MzcyMmM0ZjliOGU1NmM0MzEwOTU0MDMyN18wLTMtMS0xLTQyMDk4_e5245ca9-a2b4-4ff1-b9b5-99948f0eb88e">83-2771572</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:106%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(IRS Employer Identification No.)</span></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGFibGU6YjJhNGM2OTM3MjJjNGY5YjhlNTZjNDMxMDk1NDAzMjcvdGFibGVyYW5nZTpiMmE0YzY5MzcyMmM0ZjliOGU1NmM0MzEwOTU0MDMyN18zLTAtMS0xLTQyMDk4_1e5ae54d-d9f6-444a-9536-ad4a9b0d9219">320 West 37th Street</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGFibGU6YjJhNGM2OTM3MjJjNGY5YjhlNTZjNDMxMDk1NDAzMjcvdGFibGVyYW5nZTpiMmE0YzY5MzcyMmM0ZjliOGU1NmM0MzEwOTU0MDMyN180LTAtMS0xLTQyMDk4_666c499b-ad74-4d1e-91c8-33e8c0204c43">New York,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGFibGU6YjJhNGM2OTM3MjJjNGY5YjhlNTZjNDMxMDk1NDAzMjcvdGFibGVyYW5nZTpiMmE0YzY5MzcyMmM0ZjliOGU1NmM0MzEwOTU0MDMyN180LTEtMS0xLTQyMDk4_28847212-3e78-4b1c-a0a4-0f2538587756">NY</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGFibGU6YjJhNGM2OTM3MjJjNGY5YjhlNTZjNDMxMDk1NDAzMjcvdGFibGVyYW5nZTpiMmE0YzY5MzcyMmM0ZjliOGU1NmM0MzEwOTU0MDMyN180LTMtMS0xLTQyMDk4_bf737b4f-5e0e-4d70-b7ff-d229f93ae772">10018</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="padding-right:-0.07pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGV4dHJlZ2lvbjoxZDc2MWY2ZGY0MTA0ZGRlOTcyMWRlMWQ2YzNjZTczZF8xNTI1_85579f17-86a4-4de5-befd-a9b63d26912f">917</ix:nonNumeric>) <ix:nonNumeric contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGV4dHJlZ2lvbjoxZDc2MWY2ZGY0MTA0ZGRlOTcyMWRlMWQ2YzNjZTczZF8xNTMy_2f8a386b-cc7c-4f88-92ab-bcb61f251fd8">580-3099</ix:nonNumeric></span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.911%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:0.2pt;padding-right:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-bottom:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGV4dHJlZ2lvbjoxZDc2MWY2ZGY0MTA0ZGRlOTcyMWRlMWQ2YzNjZTczZF8xNTI2_b7514060-3bd5-49d5-a793-4f8d4f25d850">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGV4dHJlZ2lvbjoxZDc2MWY2ZGY0MTA0ZGRlOTcyMWRlMWQ2YzNjZTczZF8xNTI3_6ac66f02-50b2-4888-8c0e-1d68792f8ce8">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-bottom:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGV4dHJlZ2lvbjoxZDc2MWY2ZGY0MTA0ZGRlOTcyMWRlMWQ2YzNjZTczZF8xNTI4_1c7d9c7a-1444-4fce-9dd5-b0823d0e0429">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-bottom:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGV4dHJlZ2lvbjoxZDc2MWY2ZGY0MTA0ZGRlOTcyMWRlMWQ2YzNjZTczZF8xNTMx_8a5b26a6-db4a-4251-b81a-08e7d742d0d7">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-bottom:12pt;padding-left:0.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.476%"><tr><td style="width:1.0%"></td><td style="width:36.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.702%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.824%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.426%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.153%"></td><td style="width:0.0%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.5pt;padding-right:2.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Trading Symbol(s)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGFibGU6NjEyOTI1MTg1MmFkNDYxMWI1NzM1MzQyYTExZTNhNzgvdGFibGVyYW5nZTo2MTI5MjUxODUyYWQ0NjExYjU3MzUzNDJhMTFlM2E3OF8xLTAtMS0xLTQyMDk4_52c1e794-06f3-4278-9f6d-3cfa5ea76431">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGFibGU6NjEyOTI1MTg1MmFkNDYxMWI1NzM1MzQyYTExZTNhNzgvdGFibGVyYW5nZTo2MTI5MjUxODUyYWQ0NjExYjU3MzUzNDJhMTFlM2E3OF8xLTItMS0xLTQyMDk4_bae677f8-2830-4e6c-8510-cf93cc024cf2">IMVT</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGFibGU6NjEyOTI1MTg1MmFkNDYxMWI1NzM1MzQyYTExZTNhNzgvdGFibGVyYW5nZTo2MTI5MjUxODUyYWQ0NjExYjU3MzUzNDJhMTFlM2E3OF8xLTQtMS0xLTQyMDk4_0e4d2df2-3cc8-4004-bd38-06b3b8fd1885">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:0.2pt;padding-right:15pt"><span><br/></span></div><div style="padding-right:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt;padding-left:0.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company  <ix:nonNumeric contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGV4dHJlZ2lvbjoxZDc2MWY2ZGY0MTA0ZGRlOTcyMWRlMWQ2YzNjZTczZF8xNTI5_8fd0a1d6-4231-46ba-bf6b-c5c6dfb115d3">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;padding-left:0.2pt;padding-right:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i2730ca93fc8e4cb0bb934ec18c372901_7"></div><hr style="page-break-after:always"/><div style="min-height:13.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt;padding-right:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On August 5, 2022, Immunovant, Inc., or the Company, issued a press release announcing its financial results for its first quarter ended June 30, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Current Report shall not be incorporated by reference in any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d) Exhibits</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.670%"><tr><td style="width:1.0%"></td><td style="width:14.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Description</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit99120220805.htm">Press release dated August 5, 2022.</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i2730ca93fc8e4cb0bb934ec18c372901_10"></div><hr style="page-break-after:always"/><div style="min-height:13.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.945%"><tr><td style="width:1.0%"></td><td style="width:55.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.419%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">IMMUNOVANT, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ Eva Renee Barnett</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Eva Renee Barnett</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date: August 5, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99120220805.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic8204cddb39c40b29be10aec41582d8a_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="padding-left:396pt;text-align:right;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Exhibit 99.1</font></div><div style="text-align:center;text-indent:18pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended June 30, 2022</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NEW YORK, August 05, 2022 (GLOBE NEWSWIRE) &#8211; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunovant, Inc. (Nasdaq&#58; IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today reported recent company updates and financial results for its fiscal first quarter ended June 30, 2022. </font></div><div><font><br></font></div><div><font style="color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Updates and Anticipated Milestones&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Immunovant initiated a pivotal clinical trial of batoclimab in Myasthenia Gravis in June 2022. Top-line data from the trial are expected in the second half of calendar year 2024. For its program in Thyroid Eye Disease, Immunovant achieved alignment with the United States Food and Drug Administration (FDA) Division of Ophthalmology on plans for two placebo-controlled pivotal clinical trials. The trials are expected to begin in the second half of calendar year 2022 with top-line data for both expected in the first half of calendar year 2025.</font></div><div><font><br></font></div><div><font style="color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Additional Pipeline Programs&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Immunovant plans on announcing two new indications for batoclimab on an investor call scheduled for Wednesday, September 7, 2022 at 8&#58;00AM ET. During this call, Immunovant also plans to announce the third indication (in addition to MG and TED) it will initiate as a pivotal trial in calendar year 2022. Call-in information and webcast access for this investor call to be shared at a later date.</font></div><div><font><br></font></div><div><font style="color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Highlights for Fiscal First Quarter Ended June 30, 2022&#58;</font></div><div><font><br></font></div><div><font style="color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> During the three months ended June 30, 2022, Immunovant made cash payments higher than in recent quarters primarily due to costs for contract manufacturing of drug substance and upfront payments for Immunovant&#8217;s Phase 3 clinical trials. Collectively, these CMC and clinical trial payments in the first fiscal quarter totaled approximately $31 million. The concentration of these payments into a single quarter was anticipated as part of the Company&#8217;s long-term cash planning. Lower cash expenditures are expected next quarter and the higher cash expenditures this quarter do not alter the Company&#8217;s anticipated cash runway. Given the variable timing of manufacturing and clinical trial costs, Immunovant expects to continue to incur fluctuating quarterly operating cash flows in the future.  Consistent with prior guidance, Immunovant&#8217;s cash balance of $427 million as of June 30, 2022 is expected to provide cash runway into calendar year 2025.</font></div><div><font><br></font></div><div><font style="color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">R&#38;D Expenses&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development expenses were $28.4 million for the three months ended June 30, 2022, compared to $18.7 million for the three months ended June 30, 2021. The year-over-year increase was primarily due to higher personnel-related expenses (including stock-based compensation) and higher costs related to cross-indication clinical studies and research, reflecting Immunovant&#8217;s investment to support strategic objectives as the Company resumed its clinical activities and evaluated potential new indications. </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div><font style="color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">G&#38;A Expenses&#58;</font><font style="color:#404040;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative expenses were $11.9 million for the three months ended June 30, 2022, compared to $11.2 million for the three months ended June 30, 2021. The year-over-year increase was primarily due to higher stock-based compensation and information technology costs, partially offset by lower legal and other professional fees.</font></div><div><font><br></font></div><div><font style="color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net Loss&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss was $40.4 million ($0.35 per common share) for the three months ended June 30, 2022, compared to $30.5 million ($0.31 per common share) for the three months ended June 30, 2021. Net loss for the three months ended June 30, 2022 and 2021 included $7.7 million and $3.9 million, respectively, related to non-cash stock-based compensation expense. </font></div><div><font><br></font></div><div><font style="color:#4fa7f7;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Common Stock&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of June 30, 2022, there were 116,524,158 shares of common stock issued and outstanding.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Immunovant, Inc.&#8239;  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, the Company is boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. The Company&#8217;s investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). For additional information on the Company, please visit </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">www.immunovant.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; and other similar expressions are intended to identify forward-looking statements.  Such forward looking statements include Immunovant's plan to initiate two Phase 3 clinical trials for batoclimab in TED in the second half of calendar year 2022 with expected topline data readouts in the first half of calendar year 2025&#59; Immunovant&#8217;s plan to report topline data for a Phase 3 clinical trial for batoclimab in MG in the second half of calendar year 2024&#59; the timing of the announcement of additional indications and the third pivotal trial to be initiated in calendar year 2022&#59; Immunovant&#8217;s expected cash runway&#59; and Immunovant&#8217;s plan to develop batoclimab across a broad range of autoimmune indications. All forward-looking statements are based on estimates and assumptions by Immunovant&#8217;s management that, although Immunovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Immunovant expected. Such risks and uncertainties include, among others&#58; initial results or other preliminary analyses or results of early clinical trials may not be predictive final trial results or of the results of later clinical trials&#59; the timing and availability of data from clinical trials&#59; the timing of discussions with regulatory agencies, as well as regulatory submissions and potential approvals&#59; the continued development of Immunovant&#8217;s product candidate, including the timing of the commencement of additional clinical trials and resumption of current trials&#59; Immunovant&#8217;s scientific approach, clinical trial design, indication selection and general development progress&#59; future clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release&#59; any product candidate that Immunovant develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all&#59; Immunovant&#8217;s product candidate may not be beneficial to patients, or even if approved by regulatory authorities, successfully commercialized&#59; the potential impact of the ongoing COVID-19 pandemic, geopolitical tensions, and adverse macroeconomic conditions on Immunovant&#8217;s clinical development plans and timelines&#59; Immunovant&#8217;s business is heavily dependent on the successful development, regulatory approval and commercialization of its sole product candidate, batoclimab&#59; Immunovant is at an early stage in development of batoclimab&#59; and Immunovant will require additional capital to fund its operations and advance batoclimab through clinical development. These and other risks and uncertainties are more fully described in Immunovant&#8217;s periodic and other reports filed with the Securities and Exchange Commission (SEC), including in the section titled &#8220;Risk Factors&#8221; in Immunovant&#8217;s most </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">recent Annual Report on Form 10-K, its Form 10-Q to be filed with the SEC on August 5, 2022, and Immunovant&#8217;s subsequent filings with the SEC</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any forward-looking statement speaks only as of the date on which it was made. Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">IMMUNOVANT, INC. </font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Condensed Consolidated Statements of Operations </font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">(Unaudited, in thousands, except share and per share data)</font></div><div style="margin-bottom:6pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.787%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.787%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.905%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="18" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Three Months Ended June 30,</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2022</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2021</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">28,429</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">18,705</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">General and administrative</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">11,946</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">11,181</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total operating expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">40,375</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">29,886</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other (income) expense</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(354)</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">626</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Loss before provision (benefit) for income taxes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(40,021)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(30,512)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Provision (benefit) for income taxes</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">352</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(41)</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Net loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(40,373)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(30,471)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccecff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss per common share &#8212; basic and diluted</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="3" style="background-color:#ccecff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.35)</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccecff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="3" style="background-color:#ccecff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.31)</font></td><td colspan="3" style="background-color:#ccecff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Weighted average common shares outstanding &#8212; basic and diluted</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">116,557,508</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">97,976,982</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">IMMUNOVANT, INC.</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Condensed Consolidated Balance Sheets</font></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited, in thousands, except share and per share data)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:125%">June 30,</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:125%">March 31,</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2022</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:125%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Assets</font></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Current assets&#58;</font></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">427,205</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">493,817</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accounts receivable</font></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">13,177</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">12,229</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Prepaid expenses and other current assets</font></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">15,922</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6,885</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total current assets</font></td><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">456,304</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">512,931</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating lease right-of-use assets</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,024</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,303</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Property and equipment, net</font></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">328</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">330</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">458,656</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">515,564</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Liabilities and Stockholders&#8217; Equity</font></td><td colspan="9" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Current liabilities&#58;</font></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accounts payable</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,066</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">18,629</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accrued expenses</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">19,013</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">24,746</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Current portion of operating lease liabilities</font></td><td colspan="6" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,165</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,145</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total current liabilities</font></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">21,244</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">44,520</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating lease liabilities, net of current portion</font></td><td colspan="6" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">919</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,219</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total liabilities</font></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">22,163</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">45,739</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Commitments and contingencies</font></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Stockholders&#8217; equity&#58;</font></div></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Series A preferred stock, par value $0.0001 per share, 10,000 shares authorized, issued and outstanding at June 30, 2022 and March 31, 2022</font></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at June 30, 2022 and March&#160;31, 2022</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 116,524,158 shares issued and outstanding at June 30, 2022 and 500,000,000 shares authorized, 116,482,899 shares issued and outstanding at March&#160;31, 2022</font></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">12</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">12</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Additional paid-in capital</font></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">832,504</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">824,796</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accumulated other comprehensive (loss) income</font></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(263)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">404</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accumulated deficit</font></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(395,760)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(355,387)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total stockholders&#8217; equity</font></td><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">436,493</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">469,825</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total liabilities and stockholders&#8217; equity</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">458,656</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">515,564</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contact&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tom Dorney, MS, MBA</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investor Relations</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Immunovant, Inc.</font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">info&#64;immunovant.com</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>imvt-20220805.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:0bd1ddaa-ab60-4adc-889e-0e588e84478b,g:a9c6a1e5-c9ea-4488-82d8-47e44a56cdfe-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:imvt="http://immunovant.com/20220805" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://immunovant.com/20220805">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="imvt-20220805_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="imvt-20220805_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://immunovant.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>imvt-20220805_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:0bd1ddaa-ab60-4adc-889e-0e588e84478b,g:a9c6a1e5-c9ea-4488-82d8-47e44a56cdfe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_ad469aea-d4fe-441e-9175-c3698549f726_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_70379b80-1bd8-41c5-bd0d-0573153d8a8c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_01b80e61-d694-4237-b3e5-c1bbcfa214f0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_11fa0c7a-66b7-486e-b6bb-a16cf22b42d1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_1c76eb15-d7ff-4cdb-8eaa-2c7696a7ab56_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_f7bd4c9d-aad7-4d0b-9ef6-4bb0092ed780_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_2931af01-6674-4ee3-8976-290c4177f7ab_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8a1aae3f-e0d7-4bdd-9acf-d7edaf97c8e8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8c5a0434-1bf6-438a-a155-2dfcdabb13b1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_737edc5f-48dd-4f5b-beff-7a026865091f_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bb55587d-4a9b-49c7-860c-5a2feca1c543_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_daa14082-ef90-434a-9eaa-9ac3cad4d850_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_954f27cd-4fac-4b2c-9a7a-ff106abfe27f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_726644fc-b76e-407f-b5d6-bbd47bac40a6_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6378fd4e-39a1-4206-87be-590439359ffa_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_93703eb7-8ee0-4282-9bed-9e69b0e04d22_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_d97522b7-6a09-46b5-b5e5-4feb5c07df81_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e8ddb31f-735e-4835-87ef-d87c42daf29c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_10b6639d-968f-42b3-8e84-22411c2c6933_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_3bf58291-51f5-48f4-bf56-8fd60c1b1e4b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5c458597-3056-4116-bc17-02cc0f7b3c64_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_d7f87d8c-9928-4bbc-adf7-0c1b0246f7f8_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>imvt-20220805_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:0bd1ddaa-ab60-4adc-889e-0e588e84478b,g:a9c6a1e5-c9ea-4488-82d8-47e44a56cdfe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://immunovant.com/role/Cover" xlink:type="simple" xlink:href="imvt-20220805.xsd#Cover"/>
  <link:presentationLink xlink:role="http://immunovant.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_42062cd2-fc6e-4806-aa87-e6ae62c76acf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:to="loc_dei_DocumentType_42062cd2-fc6e-4806-aa87-e6ae62c76acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_503b7eaf-d97d-49c1-ade0-d57eb580d991" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:to="loc_dei_DocumentPeriodEndDate_503b7eaf-d97d-49c1-ade0-d57eb580d991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_cd84c3ac-47b5-4fdb-8c32-c3cc581cec96" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:to="loc_dei_EntityRegistrantName_cd84c3ac-47b5-4fdb-8c32-c3cc581cec96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_032a2293-8101-410b-ae6a-21de7d845edf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:to="loc_dei_EntityIncorporationStateCountryCode_032a2293-8101-410b-ae6a-21de7d845edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a78c3ffa-49c9-4b18-b4a0-d3855fd6dfd6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:to="loc_dei_EntityFileNumber_a78c3ffa-49c9-4b18-b4a0-d3855fd6dfd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_58c71ce3-0d35-4995-b196-c5364d0949fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:to="loc_dei_EntityTaxIdentificationNumber_58c71ce3-0d35-4995-b196-c5364d0949fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_46fe4baa-fa92-4a41-a522-10b180a67b82" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:to="loc_dei_EntityAddressAddressLine1_46fe4baa-fa92-4a41-a522-10b180a67b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_5077cd46-b2b1-4241-888d-da0c7a2dfdeb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:to="loc_dei_EntityAddressCityOrTown_5077cd46-b2b1-4241-888d-da0c7a2dfdeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c948649b-41ca-4154-89e8-7cc5627ba831" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:to="loc_dei_EntityAddressStateOrProvince_c948649b-41ca-4154-89e8-7cc5627ba831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f562d6e8-60d6-4190-9b0d-fa6865ee2ff6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:to="loc_dei_EntityAddressPostalZipCode_f562d6e8-60d6-4190-9b0d-fa6865ee2ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_68de7c4c-0b5c-401c-9313-06b075f591cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:to="loc_dei_CityAreaCode_68de7c4c-0b5c-401c-9313-06b075f591cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_fd8a1c72-fc24-41e4-ada6-338c5814cb3e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:to="loc_dei_LocalPhoneNumber_fd8a1c72-fc24-41e4-ada6-338c5814cb3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_475d6d7c-8b5d-46ed-8872-d5d275884b6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:to="loc_dei_WrittenCommunications_475d6d7c-8b5d-46ed-8872-d5d275884b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_0e25792d-9073-443f-b3a8-e530b550d0c0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:to="loc_dei_SolicitingMaterial_0e25792d-9073-443f-b3a8-e530b550d0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_faa0c597-4cf1-4913-8989-6a8222115686" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:to="loc_dei_PreCommencementTenderOffer_faa0c597-4cf1-4913-8989-6a8222115686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_13e8d53e-25cf-4050-a156-5050d5a8406c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_13e8d53e-25cf-4050-a156-5050d5a8406c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8d767825-303d-40b0-8042-c400d9ab5344" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:to="loc_dei_Security12bTitle_8d767825-303d-40b0-8042-c400d9ab5344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ef9ccfdb-c640-486b-87e0-d841e132a5cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:to="loc_dei_TradingSymbol_ef9ccfdb-c640-486b-87e0-d841e132a5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4236bace-11ed-4ddb-bc35-ce50b3828c53" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:to="loc_dei_SecurityExchangeName_4236bace-11ed-4ddb-bc35-ce50b3828c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e5326850-95f8-4fd6-b924-1532e4f7edc6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:to="loc_dei_EntityEmergingGrowthCompany_e5326850-95f8-4fd6-b924-1532e4f7edc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2bb9d6a6-45ab-4101-b54b-e82459d6426e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:to="loc_dei_EntityCentralIndexKey_2bb9d6a6-45ab-4101-b54b-e82459d6426e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_143e602a-e1ff-4211-bcaf-917cbbadd195" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e0f34e5-2b06-4c19-8f2c-e3fe690a8ace" xlink:to="loc_dei_AmendmentFlag_143e602a-e1ff-4211-bcaf-917cbbadd195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140395508170960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 05, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  05,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IMMUNOVANT, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-2771572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">320 West 37th Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">580-3099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMVT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001764013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>imvt-20220805_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="imvt-20220805.xsd" xlink:type="simple"/>
    <context id="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764013</identifier>
        </entity>
        <period>
            <startDate>2022-08-05</startDate>
            <endDate>2022-08-05</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV80L2ZyYWc6YTQwNWU5ZmRiNTIzNDBmNGIzMjI5YWQ3MzA4YzMzYTEvdGFibGU6OGJjMTgwNDlmYmM0NDVlY2I2NWI1MTNiNGM1YmY4NzgvdGFibGVyYW5nZTo4YmMxODA0OWZiYzQ0NWVjYjY1YjUxM2I0YzViZjg3OF8xLTEtMS0xLTQyMDk4_a23eab3a-0061-445a-a8d1-d6edf0a36211">0001764013</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV80L2ZyYWc6YTQwNWU5ZmRiNTIzNDBmNGIzMjI5YWQ3MzA4YzMzYTEvdGFibGU6OGJjMTgwNDlmYmM0NDVlY2I2NWI1MTNiNGM1YmY4NzgvdGFibGVyYW5nZTo4YmMxODA0OWZiYzQ0NWVjYjY1YjUxM2I0YzViZjg3OF8yLTEtMS0xLTQyMDk4_1bf6c508-4dbe-4cca-a8b0-beda1a317a97">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGV4dHJlZ2lvbjoxZDc2MWY2ZGY0MTA0ZGRlOTcyMWRlMWQ2YzNjZTczZF8xNTMw_0d2ef706-9bfc-49cf-bc24-00b3f4b1dfd0">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGV4dHJlZ2lvbjoxZDc2MWY2ZGY0MTA0ZGRlOTcyMWRlMWQ2YzNjZTczZF8yMjg_ca15383d-f1f3-48b4-b794-3f519fab669b">2022-08-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGV4dHJlZ2lvbjoxZDc2MWY2ZGY0MTA0ZGRlOTcyMWRlMWQ2YzNjZTczZF8xNTI0_49c1d528-fb70-4410-83ec-f84d041ee312">IMMUNOVANT, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGFibGU6YjJhNGM2OTM3MjJjNGY5YjhlNTZjNDMxMDk1NDAzMjcvdGFibGVyYW5nZTpiMmE0YzY5MzcyMmM0ZjliOGU1NmM0MzEwOTU0MDMyN18wLTAtMS0xLTQyMDk4_97d7c6a7-36c4-46e0-ba08-782d3a387cb8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGFibGU6YjJhNGM2OTM3MjJjNGY5YjhlNTZjNDMxMDk1NDAzMjcvdGFibGVyYW5nZTpiMmE0YzY5MzcyMmM0ZjliOGU1NmM0MzEwOTU0MDMyN18wLTItMS0xLTQyMDk4_9ad0599e-4cf0-4005-8db4-f3b97b0933e5">001-38906</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGFibGU6YjJhNGM2OTM3MjJjNGY5YjhlNTZjNDMxMDk1NDAzMjcvdGFibGVyYW5nZTpiMmE0YzY5MzcyMmM0ZjliOGU1NmM0MzEwOTU0MDMyN18wLTMtMS0xLTQyMDk4_e5245ca9-a2b4-4ff1-b9b5-99948f0eb88e">83-2771572</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGFibGU6YjJhNGM2OTM3MjJjNGY5YjhlNTZjNDMxMDk1NDAzMjcvdGFibGVyYW5nZTpiMmE0YzY5MzcyMmM0ZjliOGU1NmM0MzEwOTU0MDMyN18zLTAtMS0xLTQyMDk4_1e5ae54d-d9f6-444a-9536-ad4a9b0d9219">320 West 37th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGFibGU6YjJhNGM2OTM3MjJjNGY5YjhlNTZjNDMxMDk1NDAzMjcvdGFibGVyYW5nZTpiMmE0YzY5MzcyMmM0ZjliOGU1NmM0MzEwOTU0MDMyN180LTAtMS0xLTQyMDk4_666c499b-ad74-4d1e-91c8-33e8c0204c43">New York,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGFibGU6YjJhNGM2OTM3MjJjNGY5YjhlNTZjNDMxMDk1NDAzMjcvdGFibGVyYW5nZTpiMmE0YzY5MzcyMmM0ZjliOGU1NmM0MzEwOTU0MDMyN180LTEtMS0xLTQyMDk4_28847212-3e78-4b1c-a0a4-0f2538587756">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGFibGU6YjJhNGM2OTM3MjJjNGY5YjhlNTZjNDMxMDk1NDAzMjcvdGFibGVyYW5nZTpiMmE0YzY5MzcyMmM0ZjliOGU1NmM0MzEwOTU0MDMyN180LTMtMS0xLTQyMDk4_bf737b4f-5e0e-4d70-b7ff-d229f93ae772">10018</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGV4dHJlZ2lvbjoxZDc2MWY2ZGY0MTA0ZGRlOTcyMWRlMWQ2YzNjZTczZF8xNTI1_85579f17-86a4-4de5-befd-a9b63d26912f">917</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGV4dHJlZ2lvbjoxZDc2MWY2ZGY0MTA0ZGRlOTcyMWRlMWQ2YzNjZTczZF8xNTMy_2f8a386b-cc7c-4f88-92ab-bcb61f251fd8">580-3099</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGV4dHJlZ2lvbjoxZDc2MWY2ZGY0MTA0ZGRlOTcyMWRlMWQ2YzNjZTczZF8xNTI2_b7514060-3bd5-49d5-a793-4f8d4f25d850">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGV4dHJlZ2lvbjoxZDc2MWY2ZGY0MTA0ZGRlOTcyMWRlMWQ2YzNjZTczZF8xNTI3_6ac66f02-50b2-4888-8c0e-1d68792f8ce8">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGV4dHJlZ2lvbjoxZDc2MWY2ZGY0MTA0ZGRlOTcyMWRlMWQ2YzNjZTczZF8xNTI4_1c7d9c7a-1444-4fce-9dd5-b0823d0e0429">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGV4dHJlZ2lvbjoxZDc2MWY2ZGY0MTA0ZGRlOTcyMWRlMWQ2YzNjZTczZF8xNTMx_8a5b26a6-db4a-4251-b81a-08e7d742d0d7">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGFibGU6NjEyOTI1MTg1MmFkNDYxMWI1NzM1MzQyYTExZTNhNzgvdGFibGVyYW5nZTo2MTI5MjUxODUyYWQ0NjExYjU3MzUzNDJhMTFlM2E3OF8xLTAtMS0xLTQyMDk4_52c1e794-06f3-4278-9f6d-3cfa5ea76431">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGFibGU6NjEyOTI1MTg1MmFkNDYxMWI1NzM1MzQyYTExZTNhNzgvdGFibGVyYW5nZTo2MTI5MjUxODUyYWQ0NjExYjU3MzUzNDJhMTFlM2E3OF8xLTItMS0xLTQyMDk4_bae677f8-2830-4e6c-8510-cf93cc024cf2">IMVT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGFibGU6NjEyOTI1MTg1MmFkNDYxMWI1NzM1MzQyYTExZTNhNzgvdGFibGVyYW5nZTo2MTI5MjUxODUyYWQ0NjExYjU3MzUzNDJhMTFlM2E3OF8xLTQtMS0xLTQyMDk4_0e4d2df2-3cc8-4004-bd38-06b3b8fd1885">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOjI3MzBjYTkzZmM4ZTRjYjBiYjkzNGVjMThjMzcyOTAxL3NlYzoyNzMwY2E5M2ZjOGU0Y2IwYmI5MzRlYzE4YzM3MjkwMV8xL2ZyYWc6MWQ3NjFmNmRmNDEwNGRkZTk3MjFkZTFkNmMzY2U3M2QvdGV4dHJlZ2lvbjoxZDc2MWY2ZGY0MTA0ZGRlOTcyMWRlMWQ2YzNjZTczZF8xNTI5_8fd0a1d6-4231-46ba-bf6b-c5c6dfb115d3">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M83^ ]RLIS4?#GECS?S@,_P-02P,$%     @ \3@%59^@&_"Q @  X@P   T
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( /$X!55_8->%2 0  'P0   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " #Q. 55GZ ;\+$"  #B#   #0              @ &,#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( /$X!567BKL<P    !,"   +
M  "  6@/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( /$X!56JQ"(6,P$  "("
M   /              "  5$0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" #Q. 55)!Z;HJT   #X 0  &@              @ &Q$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #Q. 5599!YDAD!  #/ P
M$P              @ &6$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"  #@$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="imvt-20220805.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immunovant.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="imvt-20220805.htm">imvt-20220805.htm</File>
    <File>exhibit99120220805.htm</File>
    <File>imvt-20220805.xsd</File>
    <File>imvt-20220805_lab.xml</File>
    <File>imvt-20220805_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "imvt-20220805.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "imvt-20220805.htm"
     ]
    },
    "labelLink": {
     "local": [
      "imvt-20220805_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "imvt-20220805_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "imvt-20220805.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "imvt",
   "nsuri": "http://immunovant.com/20220805",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imvt-20220805.htm",
      "contextRef": "i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://immunovant.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "imvt-20220805.htm",
      "contextRef": "i69024712ba8342c4a312a2abed1a70a6_D20220805-20220805",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://immunovant.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001764013-22-000083-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001764013-22-000083-xbrl.zip
M4$L#!!0    ( /$X!578G!:JO1<  /[F   6    97AH:6)I=#DY,3(P,C(P
M.# U+FAT;>T]:W/:2+;?[Z_H=7(S=I7 D@ #=B95'MO)YFZ<9&-G4OMIJY$:
MTQNAUJ@E.]Q?O^=T2R! 8"Q>,F:V-@EZ=)_WL[OU]F^77RYN__7UBO2BOD>^
M?O_CT\<+<E Y/OY1NS@^OKR])'^_O?Y$ZE73(K<A]26/N/"I=WQ\]?F '/2B
M*#@]/GYX>*@^U*HBO#N^_7:,0]6//2$DJ[J1>_#N+5Z!/QEUW_W/V[]5*N12
M.'&?^1%Q0D8CYI)8<O^._'"9_$DJE>2I"Q$,0G[7BXAMVC;Y(<*?_)[J^Q&/
M//8N'>?ML?[]]EA-\K8CW,&[MRZ_)]S]_8 [+=NL.Z[;J;6=NMFQVQUFF90Y
M=:O1LMT6_;<%0![#X_H=&0T\]OM!G_N5'L/Y3YMV$)T]<#?JG5JF^;\'X\_1
M\ X>[8@H$OU3LVJV@@B>Z H_ DA"&%G_4T\P-4U 71>0KWBL&YW6VB<P4\1^
M117J\3O_5.&O+W#?!51/K='PZ1".\$1X^LI4_YWAG4J7]KDW./WM H;IA/PW
M0P+S*I*%O*L?D/S_V:EEP6SJYT."*+SO<9^EB%N6#=A>_>KQ#H](NUVUQK')
MX)$!V@$X63@+ZARBS!MFP[A^[/=C7]Q3F/$;"T082?*>^]1W./7@BHP]N$)]
M%_Z-\)$_4'29E.1[X((H2](5(8EZC/PSIB& 3ZZ  "[YO]AGI&8:2I2GD)]'
MF(VA;Z-@?[[Z0?[UY=L_#'(>W\4R(F9#PTP./WSZ\L<5@0=N?GS\=G5$WKQJ
MV99U1E*(UP-F/1?,$9<,\M%WJN3P,Y4N_>O-JT;KC'R\_O/VR""4./ F=ZA7
MD1&]8Z3#1="C89\Z+([P.G%$/Z#^ )CFQ!+8)'S"?-KQT!KY I[TB,?O$ZX&
M3 0>(P\\ZA$:1X(C$(RX7#(JF31()%PZ(*$2&Q@LU!*2SA$G H+"TQV*5)B(
M%$[ \6\N$; N#X'X?R4RQ*9EJ$J6EZ)ZES:[S35(4:(;WS,8G_M <1XH:W_-
M/28C 6JC^54*?9@2M$ES *(4<04_)0&_%Q'*3R)@) J1F:)+.C02<+5/._ "
MN1Y0"<; YY1\".D]EWA1\5'S\%8$%9R4 *$HZ8:BKVR''HV&C+!? 7-P3G@/
M[TCF"*!FCWI=G VF!MF@(1DP^ /&K%?)^T22@E#<A;2/;][V!J'@+KD:,'*I
MQ17T9H0:=7J<W2-F:'B59U92CC-^![3ASDVD6/E>"%?Q\S*,[\BY"TZ2RRBD
M&!:0P_>7YT<P >")/P&^+T$O EC[P*6[ 6I7X $SM(U\$/C+81U1 9RB4'@>
MS)-/60FD2NDBQPD3"=)AX( 7I9"=H#9.>0 (''AOBMY:#V<.UJB66 O/(;#0
MX1KYR@.FL/VJA4(KWC8L=U;LM#" 5%#?%S'80["Z*!8^>P#ZN\!^!%^+2T:O
MU OPP#T:D1"9XA'I])@;HP#APS^8"\8%C+%!;E@0L7X'C&@S<60T(BV%OFF>
M7Y.KVRJYC$,U=0_T$T<;UPU/B@12$+4$4J;5M,=#-P,I.02IH0G5\>GK#TI7
M;J\NCT E0?  TM2,$"HSAD1K/+P^+:]5 H3W*DK"N^B3U.@X[@/K.&!?0'T=
MC$!TY*%L3)8T2D&(!,>'"@Y/$X^B4T';7&;Q'85=?X>K'M[1.+[7+O*]4LTY
M8=:8C)<0P0LJ>]O3PZ'0HQR'C)$^O-.3>;'&F#[TJ<M L&2/!'2 KD*2'HS+
M4/:46J9Q3Q*\H","M0T!=.+&#,71$3)AI3+\U,%1_;@+_]! @:EUT;_(N .1
M&ZH;BGL<@(-$LY'.BR.,(%/Q:/-,DJ\]\&^D-NU"+M#%.!$$=!Y8!L <'KNX
MOE"#3WCRX1QC?B )SM*P+$+51:4*P-?^ B0C&)B\KED$&.6!EFJO!4@B01(G
M";CIF3-3H&$AF )#>)D._H#V(1,TP<\ [B3O RXJJAPB[0G((>&]?L(;,%@^
M#%@EG\0#"_5%=&Y@K(#(;,*)^I!U#6=&<N 4"5NG7U5&)GW:!7LMT$PJBN1
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M=TGY,DL!M:R)R61FW:2;*4M 1##\?8*Y&D8<$:8=2'5GD)78A'H0CH!>@?J
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M=8$O)0O.&VG)=D8\B6N"0-9P7A@'R"O'1MI.!>?<GY-*$1DP^A.M#$@B'6;
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M0%>DR3K:KFY5P9TR#7?I^MX PP/74OK3\?LC6'I& K\E[MC9V_?0"YJDTT!
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MTVQWTJR/'/PG"J-82O(H![%>B(0++M.*\Z@_C N6B'28QV.4LR+*P[%Z<O)
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MJ"A%3)48"/2+;@2_7$O]!^/F(;EF*Y7,^KLG/DR4\1@&4 S^4YJD9;I#J]>
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M85>Z[6I%A[NU^=[;/R_8+/6D]PM02P,$%     @ \3@%5:>XF#!%"@  &%T
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MGFD.F:)UFT0-3\/-(E, C6ED-'#8]!3L1JT#]S"@%UDU%[,DB&.$) ,TB05
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M(C:?9UE=K6>?JOIS?N4 #OJ+CJJ+VSI?G;<SP83X]FR]QWSD,3H'SFL&TL4
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M8HE/T640;1I!VL#!160058I>&1:MY1MQ_1.Q@S@@IL^!UV.Y93*\+=N\O?V
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MB>ZK>Q7^8.>_4$L! A0#%     @ \3@%5=B<%JJ]%P  _N8  !8
M     ( !     &5X:&EB:70Y.3$R,#(R,#@P-2YH=&U02P$"% ,4    " #Q
M. 55<BE6_W<4  "&B@  $0              @ 'Q%P  :6UV="TR,#(R,#@P
M-2YH=&U02P$"% ,4    " #Q. 55'._" &H"  !H!P  $0
M@ &7+   :6UV="TR,#(R,#@P-2YX<V102P$"% ,4    " #Q. 55I[B8,$4*
M   870  %0              @ $P+P  :6UV="TR,#(R,#@P-5]L86(N>&UL
M4$L! A0#%     @ \3@%5=,KZ,:Q!@  V#   !4              ( !J#D
L &EM=G0M,C R,C X,#5?<')E+GAM;%!+!08     !0 % $@!  ",0      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
